CCM
RLAY icon

Coldstream Capital Management’s Relay Therapeutics RLAY Stock Holding History

Coldstream Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-341
Closed -$894 – 2854
2025
Q1 		$894 Buy
+341
New +$1.34K ﹤0.01% 3213

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Coldstream Capital Management's RLAY Position: Q2 2025 in Review

Coldstream Capital Management sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 341 shares — an estimated $894 sold.

Coldstream Capital Management first reported a position in RLAY in Q1 2025 and held it in 1 quarter. The position peaked at $894 in Q1 2025. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Coldstream Capital Management reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 341 Relay Therapeutics shares in Q2 2025, an estimated $894.
  • Coldstream Capital Management first reported a position in Relay Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Relay Therapeutics position peaked at $894 in Q1 2025.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.